Cassava Sciences Inc. faced a major setback as its Alzheimer's drug, simufilam, failed to meet critical endpoints in a Phase ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was ...

Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.

Cassava Sciences’ stock plummets 85% after its Alzheimer’s treatment trial fails. Investigations and regulatory scrutiny add ...

Elon Musk's Neuralink received approval to launch a new feasibility trial using its brain implant and an investigational ...

The Managing Director of the Niger Delta Development Commission (NDDC), Dr. Samuel Ogbuku, has affirmed President Bola Tinubu’s dedication to the sustainable development of the Niger Delta region, ...

周一，Cassava Sciences经历了市场情绪的重大转变，Rodman & Renshaw将该公司股票评级从买入下调至卖出，目标价从之前的107.00美元大幅调整至2.00美元。此次降级紧随Cassava宣布其针对阿尔茨海默病潜在治疗药物simufilam的3期ReThink-ALZ研究未能达到关键终点。

Stocks were in positive territory Monday afternoon, though off earlier highs that pushed major indexes to new records, as the equities market looks to extend last week's rally.

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...